Cargando…

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy

Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson’s disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moretti, Davide Vito, Binetti, Giuliano, Zanetti, Orazio, Frisoni, Giovanni Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051815/ https://www.ncbi.nlm.nih.gov/pubmed/24940065 http://dx.doi.org/10.2147/NDT.S64015

Ejemplares similares

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Analysis of grey matter in thalamus and basal ganglia based on EEG α3/α2 frequency ratio reveals specific changes in subjects with mild cognitive impairment
por: Moretti, Davide V, et al.
Publicado: (2012)

Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease
por: Moretti, Davide V., et al.
Publicado: (2011)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio
por: Moretti, Davide V., et al.
Publicado: (2013)

EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment
por: Moretti, Davide V., et al.
Publicado: (2013)

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
por: Shin, Junghwan, et al.
Publicado: (2020)

Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and α-Synucleinopathy
por: Wang, Peng, et al.
Publicado: (2021)

Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease
por: Kaul, Tiffany, et al.
Publicado: (2011)

Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy
por: Williams, Tosha, et al.
Publicado: (2020)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

Real-Time Quaking- Induced Conversion Assays for Prion Diseases, Synucleinopathies, and Tauopathies
por: Vascellari, Sarah, et al.
Publicado: (2022)

Paraquat, but Not Maneb, Induces Synucleinopathy and Tauopathy in Striata of Mice through Inhibition of Proteasomal and Autophagic Pathways
por: Wills, Jonathan, et al.
Publicado: (2012)

Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment
por: Moretti, D. V., et al.
Publicado: (2012)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Correction: Paraquat, but Not Maneb, Induces Synucleinopathy and Tauopathy in Striata of Mice through Inhibition of Proteasomal and Autophagic Pathways
por: Wills, Jonathan, et al.
Publicado: (2012)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's
por: Rajendran, Avanthika, et al.
Publicado: (2023)

Restless legs syndrome: differential diagnosis and management with rotigotine
por: Merlino, Giovanni, et al.
Publicado: (2009)

Globular glial tauopathy presenting clinically as atypical parkinsonism with dementia: A clinicopathological case report
por: Hoag, Thomas, et al.
Publicado: (2023)

Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study
por: Wang, Aiping, et al.
Publicado: (2016)

Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
por: Almeida, Maria do Rosário
Publicado: (2012)

Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
por: Alecu, Irina, et al.
Publicado: (2019)

Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
por: Miller, Sean J., et al.
Publicado: (2022)

Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease
por: Moretti, D. V., et al.
Publicado: (2012)

Untangling the Tauopathy for Alzheimer’s disease and parkinsonism
por: Chang, Hui-Yun, et al.
Publicado: (2018)

Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2016)

Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
por: Bi, Chenchen, et al.
Publicado: (2016)

Vascular parkinsonism sensitive to rotigotine therapy is found in aged patients: a clinical case description
por: Zarola, Flora
Publicado: (2018)

Linking the Endoplasmic Reticulum to Parkinson’s Disease and Alpha-Synucleinopathy
por: Colla, Emanuela
Publicado: (2019)

Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
por: Lai, Thuy Thi, et al.
Publicado: (2022)

α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies
por: Mizuno, Hideya, et al.
Publicado: (2010)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
por: Sekigawa, Akio, et al.
Publicado: (2015)

Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies
por: Trošt, Maja, et al.
Publicado: (2019)

ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson’s Disease-like Behavior
por: Gao, Fei, et al.
Publicado: (2022)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ujr2moa17ufqb55itlu873csjn